Eagle Pharmaceuticals, Inc. (EGRX) Shares Bought by Sei Investments Co.

Sei Investments Co. increased its holdings in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 25.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 26,818 shares of the specialty pharmaceutical company’s stock after purchasing an additional 5,357 shares during the period. Sei Investments Co. owned approximately 0.18% of Eagle Pharmaceuticals worth $1,599,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. State of Alaska Department of Revenue lifted its position in shares of Eagle Pharmaceuticals by 78.9% during the 2nd quarter. State of Alaska Department of Revenue now owns 1,592 shares of the specialty pharmaceutical company’s stock worth $125,000 after purchasing an additional 702 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its position in shares of Eagle Pharmaceuticals by 6.7% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 1,910 shares of the specialty pharmaceutical company’s stock worth $151,000 after purchasing an additional 120 shares during the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of Eagle Pharmaceuticals by 58.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,456 shares of the specialty pharmaceutical company’s stock worth $194,000 after purchasing an additional 908 shares during the last quarter. Bank of Montreal Can lifted its position in shares of Eagle Pharmaceuticals by 323.9% during the 2nd quarter. Bank of Montreal Can now owns 2,497 shares of the specialty pharmaceutical company’s stock worth $197,000 after purchasing an additional 1,908 shares during the last quarter. Finally, Campbell Newman Asset Management Inc. lifted its position in shares of Eagle Pharmaceuticals by 4.9% during the 2nd quarter. Campbell Newman Asset Management Inc. now owns 2,693 shares of the specialty pharmaceutical company’s stock worth $212,000 after purchasing an additional 126 shares during the last quarter.

Eagle Pharmaceuticals, Inc. (NASDAQ EGRX) opened at $58.01 on Wednesday. The company has a quick ratio of 5.15, a current ratio of 5.30 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $907.68, a P/E ratio of 9.59 and a beta of 1.24. Eagle Pharmaceuticals, Inc. has a twelve month low of $45.05 and a twelve month high of $97.15.

Eagle Pharmaceuticals declared that its board has approved a stock repurchase plan on Wednesday, August 9th that permits the company to repurchase $100.00 million in shares. This repurchase authorization permits the specialty pharmaceutical company to buy up to 13.3% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

EGRX has been the subject of several research analyst reports. BidaskClub raised Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. ValuEngine raised Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $75.00 price target (down previously from $81.00) on shares of Eagle Pharmaceuticals in a report on Thursday, November 9th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $75.00 price target on shares of Eagle Pharmaceuticals in a report on Friday, October 27th. Finally, Mizuho reaffirmed a “sell” rating and issued a $37.00 price target on shares of Eagle Pharmaceuticals in a report on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $62.33.

WARNING: “Eagle Pharmaceuticals, Inc. (EGRX) Shares Bought by Sei Investments Co.” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.com-unik.info/2017/12/06/eagle-pharmaceuticals-inc-egrx-shares-bought-by-sei-investments-co.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

What are top analysts saying about Eagle Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eagle Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit